Transmitted Water Disease, Assessment of Immunopathogenesis of Chronic Hepatitis B and The Carrier State of Disease
The transmission of viral hepatitis type B (HBV) is of significant public health concern. The infection result depends on how well the virus interacts with the host and in particular, on the ability to respond inherently and adaptively to the humoral and cellular immunity. The purpose of this study is to evaluate clinical, immunology and tracer status (viral). This study showed the relationship between the immune and chronic conditions of Iraqi patients who are chronic hepatitis virus B or HBV carriers. The study included (111) chronically-viral hepatitis type (b) and (112) hepatitis virus surface antigen type (b) healthy carriers from out of patients. The result of this study proved that a non-significant correlation was observed between cellular immune response (CD4 and CD8) among chronic hepatitis B patients. For CD8+ lymphocytes: there was a highly significant decrease (P<0.001) in the percentage means of the CD8+ cells in CHB patients, as compared with the carrier groups. For CD4+ lymphocytes: there was a slight decrease in the percentage of these lymphocytes in the peripheral blood of the patients, as compared with the carrier groups, a non-significant importance was recorded between them. The percentage of cytotoxic T-lymphocyte CD8+ was significantly decreased in CHB patients as compared to the carrier group. One of the deciding factors for the form of infection, and the immune response, which developed in accordance with a number of other biochemical factors and genes is chronic hepatitis B immunopathogénesis and carrier condition with the level of cellular immunity
Boonstra, A., Woltman, A.M. and H.L. Janssen (2008). Immunology of hepatitis B and hepatitis C virus infections. Best Practice and Research Clinical Gastroenterology, 22(6): 1049-1061.
Carinelli, S., Martí, M., Alegret, S. and M.I. Pividori (2015). Biomarker detection of global infectious diseases based on magnetic particles. New Biotechnology, 32(5): 521-532.
Chisari, F.V., Isogawa, M. and S.F. Wieland (2010). Pathogenesis of hepatitis B virus infection. PathologieBiologie, 58(4): 258-266.
Choi, J. (2012). Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radical Biology and Medicine, 52(7): 1135-1150.
Dongping X., Junliang F., Lei J., Hui Z., Chunbao Z., Zhengsheng Z., Jing-Min Z., Bin Z., Ming S., Xilai D., Zirong T., Yang-Xin, F. and W. Fu-Sheng (2006). Circulating and liver resident CD4+ CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. The Journal of Immunology, 177(1): 739-747.
Durantel, D. and F. Zoulim (2016). New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. Journal of Hepatology, 64(1): S117-S131.
European Association for The Study of the Liver. (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology, 67(2): 370-398.
Fahey, S., Dempsey, E. and A. Long (2014). The role of chemokines in acute and chronic hepatitis C infection. Cellular & molecular immunology, 11(1): 25-40.
Froghi, S., Grant, C.R., Tandon, R., Quaglia, A., Davidson, B. and B. Fuller (2021). New insights on the role of TRP channels in calcium signaling and immunomodulation: Review of pathways and implications for clinical practice. Clinical Reviews in Allergy & Immunology, 1-22.
Guidotti, L.G. and F.V. Chisari (2006). Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. Mech. Dis., 1: 23-61
Humby, S.A. (2017). An investigation of the effects of helminth worm infection on the capacity of HIV vaccines to boost vaccine-generated immune responses (Master’s thesis, University of Cape Town).
Isogawa, M., Chung, J., Murata, Y., Kakimi, K. and F.V. Chisari (2013). CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathology, 9(7): e1003490.
Janssen, H.L., Brunetto, M. R., Kim, Y. J., Ferrari, C., Massetto, B., Nguyen, A.H. and E.J. Gane (2018). Safety, efficacy and pharmacodynamics of vesatolimod (GS- 9620) in virally suppressed patients with chronic hepatitis B. Journal of Hematology, 68(3): 431-440.
Khan, A.A., Srivastava, R., Vahed, H., Roy, S., Walia, S.S., Kim, G.J. and L. Ben Mohamed (2018). Human asymptomatic epitope peptide/CXCL10-based prime/pull vaccine induces herpes simplex virus-specific gamma interferon-positive CD107+ CD8+ T cells that infiltrate the corneas and trigeminal ganglia of humanized HLA transgenic rabbits and protect against ocular herpes challenge. Journal of Virology, 92(16).
Khong, H. and W.W. Overwijk (2016). Adjuvants for peptidebased cancer vaccines. Journal for immunotherapy of Cancer, 4(1): 1-11.
Kleiner, D.E., Chalasani, N.P., Lee, W.M., Fontana, R.J., Bonkovsky, H.L., Watkins, P.B. and DILIN, Drug-Induced Liver Injury Network. (2014). Hepatic histological findings in suspected drug-induced liver injury: systematicevaluation and clinical associations. Hepatology, 59(2): 661-670.
Knolle, P.A. and R. Thimme (2014). Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology, 146(5): 1193-1207.
Lee, C.K., Han, K.H., Suh, J.H., Cho, Y.S., Won, S.Y., Chon, C.Y. and I.S. Park (2005). HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy. The Korean Journal of Hepatology, 11(1): 34-42.
Mizukoshi, E., Sidney, J., Livingston, B., Ghany, M., Hoofnagle, J.H., Sette, A. and B. Rehermann (2004). Cellular immune responses to the hepatitis B virus polymerase. The Journal of Immunology, 173(9): 5863- 5871.
Peng, G., Li, S., Wu, W., Tan, X., Chen, Y. and Z.Chen (2008). PD-1 upregulation is associated with HBVspecific T cell dysfunction in chronic hepatitis B patients. Molecular Immunology, 45(4): 963-970.
Penna, A., Prete, G.D., Cavalli, A. and A. Bertotteti (2007). Predominant T helper1 cytokine profile of hepatitis B virus nucleocapsid- specific T-cells in acute self- limited hepatitis B. Hepatology, 25: 1022.
Perrella, A., Recioppi, L. and L. Atripaldi (2006). HBV vaccination with evidence of productive antibodies titer induces CD8+ / CD25+ T cells. Digestive, 20-25.
Ponte, R., Rancez, M., Figueiredo-Morgado, S., Dutrieux, J., Fabre-Mersseman, V., Charmeteau-de-Muylder, B. and A. Couëdel-Courteille (2017). Acute simian immunodeficiency virus infection triggers early and transient interleukin-7 production in the gut, leading to enhanced local chemokine expression and intestinal immune cell homing. Frontiers in Immunology, 8: 588
Puoti, M., Torti, C., Bruno, R., Filice, G. and G. Carosi (2006). Natural history of chronic hepatitis B in coinfected patients. Journal of Hepatology, 44: S65-S70.
Puro, R. and R.J. Schneider (2007). Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. Journal of Virology, 81(14): 7351-7362.
Ramalingam, S. (2015). Study of seroprevalence of hepatitis B virus in medico legal autopsies (Doctoral dissertation, Madras Medical College, Chennai).
Rehermann, B. (2013). Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nature Medicine, 19(7): 859-868.
Salpini, R., Colagrossi, L., Bellocchi, M.C., Surdo, M., Becker, C., Alteri, C., Maurizio, P., Mariarosaria, E., Chiara D’., Aldo, M., Massimo, M., Cesare, S., Loredana,S., Massimo, A., Mario, A., Jens, V. and P.V. Svicher (2015). Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology, 61(3): 823-833.
Sierra-Davidson, K. (2016). Single-cell transcriptional analysis of malaria-specific t lymphocytes following vaccination and protection in humans (Doctoral dissertation, University of Oxford).
Sitia, G., Iannacone, M., Müller, S., Bianchi, M.E. and L.G. Guidotti (2007). Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. Journal of leukocyte biology, 81(1): 100-107.
Spickett, G. (2019). Oxford handbook of clinical immunology and allergy. Oxford University Press, USA.
Stanley, W.J. (2018). Activation of islet inflammation by cytokine signalling in pancreatic beta cells: Understanding the role of protein tyrosine phosphatases (Doctoral dissertation).
Trépo, C., Chan, H.L. and A. Lok (2014). Hepatitis B virus infection. The Lancet, 384(9959): 2053-2063.
Wang, L., Wang, K. and Z.Q. Zou (2015). Crosstalk between innate and adaptive immunity in hepatitis B virus infection. World Journal of Hepatology, 7(30): 2980.
Weidt, G., Utermöhlen, O., Heukeshoven, J., LehmannGrube, F. and W. Deppert (1998). Relationship among immunodominance of single CD8+ T cell epitopes, virus load, and kinetics of primary antiviral CTL response. The Journal of Immunology, 160(6): 2923-2931.
Wherry, E.J. and M. Kurachi (2015). Molecular and cellular insights into T cell exhaustion. Nature Reviews Immunology, 15(8): 486-499.
Zhang, Y., Cobleigh, M.A., Lian, J.Q., Huang, C.X., Booth, C.J., Bai, X.F. and M.D.Robek (2011). A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology, 141(5): 1897-1906.
Zhou, P., Xu, J., Dai, M., Shi, Y., Wu, G., Fang, Y. and X. Yan (2018). The immunosuppressive effects of CD 4+ CD 25+ regulatory T cells on dendritic cells in patients with chronic hepatitis B. Journal of Viral Hepatitis, 25(6): 733-741.
Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. and T. Yamashita (2018). Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. The Lancet Oncology, 19(7): 940-952.